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ABSTRACT 
Background and objective : 3, 4-Methylenedioxymethamphetamine (MDMA) is a powerful central nervous system stimulant 
that acts by increasing the activity of several neurotransmitter systems. This study aimed to investigate the effect of different 
doses of MDMA on the level of serotonin in the brain measured from the cerebrospinal fluid (CSF) and their effects on the 
neurons. Materials and methods : Twenty-six adult male rats were divided into 4 groups. The control group (n=7) received 
intraperitoneal (IP) injections of 1 mL/gm normal saline twice daily for one week. The MDMA treated groups (n= 6/7) were 
further subdivided into 3 groups, each receiving 5, 10 or 15mg/kg MDMA intraperitoneal (IP) injections twice daily for one 
week ; respectively. 24 hours after the last injection of the rats, the CSF was collected. The brains were dissected and 
processed for paraffin sections and stained by cresyl etch violet stain. Histology, morphometry and statistical analysis were 
done. Results : The administration of different doses of MDMA significantly increased the level of serotonin in comparison 
with the control group. The morphometry study indicated that the number of intact neurons in the hippocampus significantly 
decreased following the administration of different doses of MDMA comparing to the control group. The results also 
indicated that there was a strong negative correlation between the serotonin levels and the number of intact neurons.  
Conclusion : MDMA administration even at a low dose had degenerative effects on the neurons in the hippocampus as 
evidenced by morphometric study, and the intake should be avoided. 
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INTRODUCTION 
 
3, 4-Methylenedioxymethamphetamine (MDMA) was discovered in 1914 by a biochemist Anton Kollisch, who 
worked for German pharmaceutical company Merck. In the mid-1980s, following a short period of experimental use 
of MDMA as an adjunct in psychotherapy, the drug became a common recreational drug of abuse [1-3]. The drug 
has some resemblance to hallucinogen mescaline [4]. The psychological effects of MDMA last for 3 to 5 hours per 
administration, and the user feels relaxed, happy, empathic and close to others [5]. 
The administration of MDMA on various experimental animals has shown to induce a selective damage to 
serotonergic axon terminals, which led to long-term depletion of serotonin neurotransmitter (5-HT).  It also caused 
an enhanced and widespread secretion of serotonin in the brain [5-7]. Another similar study by Capela and 
colleagues (2009), also found the serotonergic system as the main target of MDMA [8]. Furthermore, high dose of 
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MDMA administration also showed a persistent neurochemical disruption that particularly affected the serotonergic 
nerve terminals in rats and nonhuman primates [9, 10].  
MDMA affected the brain areas rich in serotonergic pathways [6]. MDMA administration led to serotonin 
transporter (SERT) depletion in certain areas in the rat brain that included midbrain, hippocampus, hypothalamus, 
thalamus, caudate putamen and also the frontal cortex [11]. Hippocampus is one of the most important areas in the 
brain, forming part of the limbic system that contains abundant serotonin receptors [12]. This area is responsible for 
memory processing, controlling emotions, judgment, affection, and motivation [13]. Besides that, serotonin also 
plays a role in controlling various psychiatric functions such as anxiety and depression [14]. The disruption in 
serotonin secretion can lead to an altered and dysfunctional memory and learning [15-18].  
In conjunction to that, axonal degeneration to the serotonergic terminal has been observed after MDMA exposure 
due to massive efflux of the serotonin in the synaptic cleft [9, 19]. The MDMA has a great affinity with the 
presynaptic serotonin transporter [20]. Its administration leads to an alteration in the serotonin reuptake transporter, 
which leads to an increased release of serotonin into the synapse [21]. The massive increase in the level of serotonin 
in the central nervous system may cause serotonin syndrome or serotonin toxicity [22, 23]. Serotonin syndrome is 
most likely to occur within 24 hours after administration of a serotonergic substance [24]. The administration of 
MDMA regardless of the number of administration can cause long-lasting neurochemical and histological changes, 
which can be used as markers of serotonergic function in the rats’ brains [25]. 
Cerebrospinal fluid (CSF) is a colorless body fluid present in the brain and spine [26]. The CSF is secreted by cells 
lining the choroid plexuses of the brain ventricles [27]. It circulates via the interconnected system that comprises of 
four ventricles, central canal of spinal cord and subarachnoid space [28]. The CSF provides a basic mechanical and 
immunological protection to the brain [28]. The CSF also functions to shuttle waste products from the central 
nervous system into the blood [29]. Besides that, CSF also has a crucial role in homeostasis as well as in hormonal 
and signaling functions [30].  
The CSF contains more information regarding the central nervous system as it is physically in contact with the brain 
compared to the blood [31, 32]. The CSF also provides central serotonergic parameters in the study of the serotonin 
level and its main metabolites [5]. The levels of the serotonin (5-HT) and its main metabolite (5-HIAA) in the CSF 
reflect the concentration released during neuronal activity in the brains [4]. Besides that, the results from in vivo 
brain microdialysis research showed that serotonin concentrations in the extracellular fluid such as cerebrospinal 
fluid is a suitable indicator reflecting the neuronal activity of the serotonergic system [33]. Furthermore, the 
serotonin level measured from cerebrospinal fluid also provides a better index to determine a functionally active 
serotonergic system [34, 35].   
At present, there are limited data available regarding the histological changes in the brain after administration of 
MDMA and their correlation with neurotransmitter activity in the brain. Therefore, the present study aimed to assess 
the level of serotonin concentration in the CSF of the rats after administration of different doses of MDMA, and 
correlate the level of serotonin concentration with the neuronal damage. 
MATERIALS AND METHODS 
Drug and treatment protocol 
3, 4-Methylenedioxymethamphetamine (MDMA) hydrochloride was purchased from Lipomed, A.G. (Arlesheim, 
Switzerland). The MDMA was dissolved in saline (0.9% NaCl) to give a volume of 1 mL/kg. The drug was injected 
via intraperitoneal (IP) injections to the rats twice daily at 9:00 a.m. and 5:00 p.m. for one week.  
Experimental animals  
Twenty-four adult Sprague–Dawley male rats weighing 200- 250 g each were used in the study. The animals were 
purchased from Eprovider Sdn.Bhd based in Kota Bharu, Kelantan Malaysia. The rats were kept in cages consisted 
of three individuals per cage, under the stainless steel cover in the animal house, Faculty of Medicine University 
Sultan Zainal Abidin (UniSZA).  They were kept for one week for acclimatization and reduction of post-travel 
stress.  Following that, the animals were further kept under a controlled condition (12 h light :12 h dark cycle, the 
room temperature of 22±2 °C, and the relative humidity of 55±5 %) with free access to food and water. The 
experiment was approved by the Animal Experimentation Ethics Committee of UniSZA (ID : UAPREC/16/002). 
Experimental protocol 
The rats were randomly divided into four groups as follows : i. (Control group): It consisted of 7 adult male rats, 
receiving intraperitoneal (IP) injections of 1 ml/gm normal saline twice daily for one week. ii. (Treated group 1): 
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This group consisted of 6 rats, receiving 5 mg/kg MDMA (low dose). iii. (Treated group 2): This group consisted of 
7 rats, receiving 10 mg/kg MDMA (moderate dose); iv. (Treated group 3): This group consisted of 6 rats, receiving 
15 mg/kg MDMA (high dose) via intraperitoneal (IP). The drug was administered to all the groups according to the 
treatment protocol. 
All the animals were maintained up to 24 hrs after the last dose of drug administration during which the CSF 
collection was carried out. 
Cerebrospinal fluid collection 
Following 24 hours of the last injection of either saline or MDMA according to the study protocol, the CSF was 
collected from the Cisterna magna of the rats. The rats were anesthetized prior to the collection of CSF using 
ketamine with the dose of 0.15 ml/100gm body weight. The fur on the neck region of the rats was removed. The 
head position of the rats was then maintained downward at approximately 45º on the stabilizer block.  A swab 
soaked with 70% of ethanol was rubbed over the depressible surface of the rhomb between the occipital 
protuberance and the spine. A 23G butterfly needle (B|Braun Venofix) connected to 1 ml tuberculin syringe 
(TERUMO) was inserted horizontally and centrally into the cisterna magna of the rat. A gentle aspiration was 
performed to allow the CSF to flow through the needle, and get drawn slowly into the syringe. (a Modified method 
by Nirogi and colleagues (2009) [36]. 
Serotonin analysis 
The serotonin neurotransmitter level was quantified from the CSF collected from the cisterna magna of the rats. 
Serotonin ELISA test kit (DLD EA602/96) was used to quantify the serotonin level. Firstly, for the preparation of 
samples (acylation), 10 µl of standard 1-6, 10 µl of controls 1-2 and 50 µl of CSF were pipetted into the respective 
wells of the reaction plate. Next, 25 µl of acylation buffer, 200 µl of equalizing reagent, 25 µl of acylation reagent 
were pipetted into the wells, and the mixture was properly mixed immediately. The mixture was incubated for 30 
minutes at room temperature (approximately 25ºC) on an orbital shaker. An amount of 20 µl of each acylation 
samples was pipetted into respective wells on the coated microtiter strips. Following that, 100 µl of antiserum was 
pipetted into all the wells. The plate was then covered using adhesive foil, and incubated for 30 minutes at room 
temperature on an orbital shaker. After completing the incubation, the contents of the well were aspirated and the 
wells were washed thoroughly using 250 µl wash buffer, and this step was repeated for three to four times.  
The residual liquid in the wells was removed by gently tapping the inverted plate onto a clean absorbent paper. 
Later, 100 µl enzyme conjugate was pipetted into all the wells, and the enzyme conjugate was incubated for 15 
minutes at room temperature on an orbital shaker. The same washing steps were repeated to wash the remaining 
unbounded enzyme conjugate. Subsequently, 100 µl of the substrate was then pipetted into all the wells, and was 
incubated for 20 minutes at room temperature on an orbital shaker. Finally, the 100 µl stop solution was pipetted 
into all the wells. The test was read using a microplate photometer at the optical density of 450nm (reference 
wavelength between 570 and 650 nm). The test was done in triplicate. 
Histological study 
The skulls of the rats were dissected, and the brains were harvested after the rats underwent the transcardial 
perfusion procedure. The brain tissues were then immediately immersed in 10% neutral buffered formalin, and were 
fixed for 24 hrs. The tissues were dehydrated in ascending concentrations of alcohol, and cleared in xylene after 
which they were embedded in paraffin. Serial coronal sections of 4 µm in thickness were later prepared and 
subjected to Cresyl Etch Violet staining to demonstrate the neuronal cells. In this study, the intact neurons having 
clearly defined nuclear and cytoplasmic membrane with prominent nucleoli were counted.   
Morphometric study  
A morphometric study was performed to determine the number of intact neurons in the control and treated groups. 
Two main areas were selected for the study : CA1 and CA3 subfields of the hippocampus. The intact pyramidal cells 
were counted by using image software (Cell count) from five random counting frames (50 × 50 μm), and the 
average count was calculated.   
Statistical analysis  
Serotonin concentrations from the CSF and the number of intact neurons were analyzed by using Graph Pad Prism 
version 7.00 for Windows software (Graph Pad Software Inc., San Diego, CA, USA). Analysis of variance 
(ANOVA) and Student t-test were used to compare the groups. Pearson's correlation test was used for correlations 
between groups. A 95% confidence interval was recognized as a significant result. 
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RESULTS 
Serotonin levels in rat CSF after MDMA administration 
ANOVA analysis indicated that all MDMA groups (5, 10,15mg/kg) showed a significant increase in serotonin levels 
as compared to the control group (p < 0.005) after 7 days of intraperitoneal injections twice daily. However, there 
was an insignificant increase in the level of serotonin between these MDMA groups (Figure 1).   
 
Figure 1: The effects of MDMA treatments on serotonin level in CSF over 24 hours after the last injection. 
The results showed a significant increase of serotonin level in response to MDMA administration (cp < 0.05, when 
compared to the control group). 
Histology, morphometric and statistical results of the number of intact neurons in CA1 and CA3 subfields of 
the hippocampus 
The findings of this study showed that MDMA caused a dose-dependent decrease in the number of intact neurons in 
CA 1 and CA 3 subfields of the hippocampus of the rat brain, in comparison to the saline control group. The mean 
values ± S.D of the intact number of neurons in the CA1 subfield were 197.6 ± 31.46, 123.8±115, 107.4 ±7.091 and 
77.5±14.9 for saline control, 5mg/kg MDMA, 10mg/kg MDMA and 15mg/kg MDMA for treated groups; 
respectively. The mean values ± SD of the intact number of neurons in the CA3 subfield were 112.6 ± 11.4, 
78.5±6.9, 61.3 ±4.9, 47.2±6.2 for saline control, 5mg/kg, 10mg/kg and 15mg/kg MDMA for treated groups; 
respectively. A statistically significant difference was noted between the number of the intact pyramidal cells in 
MDMA treated groups compared to the control saline group (p<0.001). All sections from the MDMA treated groups 
showed a decrease in the number of intact neurons. The mean values ± S.D of the number of intact neurons in the 
CA1 and CA3 subfield are simplified in table 1 and 2 to show a comparison between each treatment group. Figure 3 
and 5 show the mean value ± SD of the decreasing intact neurons after the MDMA administration in CA 1 and CA 3 
subfields; respectively. 
In the control group, the CA1 and CA 3 subfields of the hippocampus exhibited a higher number of intact neurons 
having clearly defined cell bodies and nuclei (CA 1, Figure 2A ; CA 3, Figure 5 A).  
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Figure 2: Photomicrographs of a coronal section of the rat brain in the CA1 subfield of the hippocampus from the 
control group (Fig. 2a) and treated groups (Figs. 2c, 2d and 2e). 
Fig. 2a shows mostly intact pyramidal cells with well-defined nuclear and cytoplasmic membrane with prominent 
nucleoli (black arrow). Fig. 2b, 2c and 2d show the presence of degenerated pyramidal cells characterized by poorly 
defined nucleus and shrunken cell cytoplasm which is dark in colour.  The nucleoli are not visible (red arrows).  
There was an increasing number of degenerated pyramidal cells seen when the dose of MDMA was increased. 
Hence, the number of intact pyramidal cells is reduced per counted area (Cresyl Echt Violet ×40). 
 
Figure 3: A histogram showing mean values ± S.D (standard deviation) of the number of intact neurons in CA1 
subfield of hippocampus from the control group and treated groups with 5, 10 and 15 mg/kg MDMA. (n = 6 or 7).  
(ap < 0.001, when compared to the control group) 
Table 1: The summary of the comparative Mean ± SD of the number of intact neurons at CA 1 subfield of 
hippocampus for each dosage of MDMA treatments. 
 Number of intact neurons 
 Control 197.6 ± 31.46 
MDMA 
5 mg/kg 123.8 ± 11.5 a 
10 mg/kg 107.4± 7.091 a,c 
15 mg/kg 77.5 ± 14.9 a,b,d 
Note: a p < 0.001 when compared to control 
          b p < 0.001 when compared to 5 mg/kg 
                c p < 0.001 when compared to 15 mg/kg 
                 dp < 0.05 when compared to 10 mg/kg  
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Figure 4: Photomicrographs of a coronal section of the rat treatment, the CA3 subfield of the hippocampus from the 
control group (Figs. 4a) and treated groups (Figs. 4c, 4d and 4e). 
 Fig. 3a shows mostly intact pyramidal cells with well-defined nuclear and cytoplasmic membrane with prominent 
nucleoli (black arrow). Fig. 3b, 3c and 3d show the presence of degenerated pyramidal cells characterized by poorly 
defined nucleus and shrunken cell cytoplasm which is dark in colour.  The nucleoli were not visible (red arrows).  
There was an increasing number of degenerated pyramidal cells seen when the dose of MDMA was increased. 
Hence, the number of intact pyramidal cells was reduced per counted area (Cresyl Echt Violet ×40). 
 
Figure 5: A histogram showing mean values ± S.D (standard deviation) of the number of intact neurons in CA3 
subfield of hippocampus from the control group and treated groups with 5, 10 and 15 mg/kg MDMA. (n = 6 or 7).  
(ap < 0.001, when compared to the control group) 
Table 2: The summary of the comparative Mean ± SD of the number of intact neurons at CA 3 subfield of 
hippocampus for each dosage of MDMA treatments. 
  Number of intact neurons 
 Control 112.6 ± 11.4 
MDMA 
5 mg/kg 78.5 ± 6.9 a 
10 mg/kg 61.3± 4.9 a,c 
15 mg/kg 47.2 ± 6.2 a,b, d 
Note: a p < 0.001 when compared to control 
               b p < 0.001 when compared to 5 mg/kg 
              c p < 0.001 when compared to 15 mg/kg 
              dp < 0.05 when compared to 10 mg/kg 
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Correlation of serotonin levels in CSF with the number of intact neurons after different doses of MDMA 
administration 
Based on the results of this study, there was a trend seen in the serotonin levels comparing to the number of intact 
neurons, in which the increasing serotonin level was correlated with decreasing number of intact neurons in both 
CA1 and CA3 subfields of the hippocampus after the administration of different doses of MDMA. From the 
statistical analysis (Graph Pad PRISM), the correlation was significant and strong in CA1 (r = -0.879) and CA3 (r = 
-0.905) (p< 0.001) (Figure 5 and 6). 
 
Figure 6: The correlation between serotonin level in CSF and the number of intact pyramidal cells in the CA1 
subfield of the hippocampus (n=26). 
The graph in fig. 6 shows the inverse correlation between the number of intact pyramidal cells in CA1 subfield of 
the hippocampus and the serotonin level in the CSF of the rats (slope = -0.909 ± 0.103, r = -0.879, p < 0.001). 
 
Figure 7: The correlation between serotonin level in CSF and the number of intact pyramidal cells in the CA3 
subfield of the hippocampus (n=26). 
The graph in fig.7 indicates that there is an inverse correlation between the number of intact pyramidal cells in CA3 
subfield of the hippocampus and the serotonin level in the CSF of the rats (slope = -0.545 ± 0.053, r = -0.905, p < 
0.001). 
Table 3: Coefficient correlation (r) and the p-value of the number of intact neurons for CA 1 and CA 3 subfields of 
the hippocampus. 
Subfield Correlation of coefficient (r) p value 
CA 1 -0.879 <0.001 
CA 3 -0.905 <0.001 
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DISCUSSIONS  
In the present study, the effects of different doses of MDMA administration on the serotonin levels in the CSF of the 
rats and the number of intact neurons, which reflected the severity of neuronal damage induced by MDMA were 
observed. The results demonstrated that the intraperitoneal administration of different doses of MDMA caused a 
significant increase in serotonin level as compared to the control group (p<0.001). Serotonin levels in the CSF 
reflected the concentration released during the neuronal activity in the brain [4]. The MDMA acted by binding on 
the presynaptic serotonin transporter (SERT), subsequently enhanced the net release of serotonin into the synapse, 
and inhibited its reuptake [37-39].  
The high concentration of serotonin in the synapse improved mood and caused sensory alteration. However, chronic 
administration of MDMA caused a massive efflux of serotonin that consequently resulted in neuronal damage 
especially on the serotonergic terminals [40]. Besides that, the rapid and active release of serotonin into the synapse 
after the MDMA administration later caused long-term serotonin depletion [41].  
The current study’s findings were consistent with a human study done by McCann and colleagues (1999), in which 
the administration of MDMA showed an increasing level of serotonin in the brain [42]. In their study, they found 
that the levels of serotonin in the CSF reflected the index of global brain release. In addition, they also claimed that 
MRI or proton magnetic resonance spectroscopy would be useful to estimate the number of intact neurons after the 
neurodegenerative effects following MDMA administration, in different regions of brain.  
According to Sprague and colleagues (2003), MDMA is one of the psychostimulant drugs that causes a disturbance 
in brain functions and neurotoxicity [43]. Hippocampus is one of the regions in the brain that contains abundant 
serotonin receptors [44, 45]. The region controls the memory and learning process. Hence, chronic administration of 
MDMA may cause an alteration in the memory and learning process of the users.  
From the results of this study, the number of intact neurons in CA1 and CA3 subfields of the hippocampus was 
significantly decreased after the administration of 5mg/kg of MDMA. This indicated that MDMA caused a 
deleterious effect even at low doses. Brain tissue is very susceptible to damage due to brain microenvironmental 
changes. MDMA administration can alter the brain microenvironment by increasing its metabolite that leads to the 
production of reactive oxygen species (ROS) and protein-bound quinones, inducing the oxidative stress and 
depleting the intracellular glutathione [46]. The neurons are susceptible to the unfavorable changes in their 
environment, as their antioxidant mechanisms have limited capacity to counteract the free radicals [47, 48]. Other 
than that, the MDMA was also found to bind and activate the pre and post-synaptic serotonin receptors [49] thus 
enhancing the intracellular pathways such as adenylate cyclase, Na2+ or Ca2+ ligand gate that consequently affected 
the expression of several genes including Bcl-2 family [50]. The MDMA affected the Bcl-2 gene by downregulating 
its expression [51]. The Bcl-2 protein is responsible for apoptosis that occurs after amphetamine administration [46, 
52]. The Bcl-2 protein inhibited the release of cytochrome C from mitochondria, ultimately blocked the caspase 
activation leading to apoptosis [53]. 
In the current study, it was postulated that the increasing level of serotonin in the synapse causes neuronal damage in 
the hippocampus via excitotoxicity mechanism. Excitotoxicity occurs through a series of mechanisms that enhance 
the glutamate release, and subsequently causes an increase in the intracellular calcium levels that further cause 
activation of calcium-dependent proteolytic enzymes, free radicals formation, and activate the apoptotic pathways 
that contribute to the neuronal damage or cell death [54-56]. According to Preedy (2016), excitotoxicity is a 
neurotoxic process enhanced by the overstimulation of NMDA and AMPA glutamate receptors on the postsynaptic 
neurons. This causes an influx of Ca+ ions that activate both the apoptotic signalling, and induce necrotic cell death.  
The MDMA triggers the increase in the level of glutamate in the hippocampus, partly mediated through a non-
neuronal mechanism [57]. According to Mark and colleagues (2004), the MDMA exerts neurotoxicity effect by 
increasing the glutamate release [58]. The increase in the extracellular glutamate levels in the hippocampus is the 
result of an increase in serotonin level after MDMA exposure via activation of 5HT2 receptors [59]. After the 
activation of the 5HT2 receptors, cyclooxygenase-2 (COX-2) activity is enhanced which consequently affect the 
prostaglandins release and later results in an increase in the glutamate level released into the synapse [56, 60]. 
According to a study by Sanzgiri, Araque, & Haydon (1999) [61], the prostaglandins, specifically prostaglandin E2 
(PGE2), was activated by EP1 receptors which caused the release of glutamate within hippocampus region causing 
excitotoxicity [62, 63]. 
Therefore, the MDMA administration causes overstimulation of the NMDA receptor [64].  The activation of NMDA 
receptors consequently enhances the glutamate actions in mediating the decrease in the number of parvalbumin (PV) 
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interneurons [65]. The increase in cyclooxygenase activity is also contributed to the decrease in the number of PV 
interneurons due to GABA toxicity [60] following a massive efflux of serotonin after MDMA administration [56].   
With these findings, the researchers would like to suggest a further study with an additional exploration of the rats' 
behavior. Murnane et al., (2012), already performed a study comparing the behavioural changes in the 
neurotransmitter levels in the brain tissue after MDMA administration [66]. However, their limitation was in the 
demonstration of the histopathological changes in the brain to compare with the behavioural changes and 
neurotransmitter levels. The researchers believe that many more comparative histopathological studies can be done 
using the CSF as a tool for measuring the neurotransmitter.  
 
CONCLUSION  
 
The present study provided evidence that chronic MDMA intake exerts a deleterious effect on the brain structure in 
the CA1 and CA3 subfields of the hippocampus-mediated by an increase in the serotonin level. The damage was 
seen even at the low dose of chronic MDMA administration. Further explorative studies would be advocated for 
better understanding and comparison. 
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